Infliximab for Crohn's disease: The first 500 patients followed up through 2009

Jennifer L. Seminerio, Edward Vincent Loftus, Jr, Jean Frédéric Colombel, Prabin Thapa, William J. Sandborn

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The aim of this study was to assess the long-term usage patterns and safety of infliximab in patients with Crohn's disease in clinical practice. Methods: The medical records of 492 unselected patients treated with infliximab at Mayo Clinic were reviewed and abstracted for demographic features, usage patterns, and adverse events. Results: The patients received a median of seven infusions and had a median follow-up of 6.3 years. Twenty-eight patients (6 %) were lost to follow-up, 63 patients (13 %) had no clinical benefit, and 401 patients (80 %) had partial or complete response. Of the responding patients, 114 (28 %) received induction treatment only, 167 (42 %) received initial episodic treatment (62 switched to scheduled maintenance treatment of whom 32 [42 %] were still on infliximab at last follow-up), and 120 (30 %) received scheduled maintenance treatment (56 patients [32 %] still on infliximab at last follow-up). Three patients (0.6 %) developed septic shock and six patients (1.5 %) developed septicemia. One patient (0.2 %) developed Mycobacterium avium complex. Histoplasmosis occurred in three patients (0.6 %). The cumulative 10-year probability for developing cancer after infliximab was 9 %. Among the 31 patients developing malignancies (6 %), 15 (3 %) had solid tumors, 11 (2 %) had melanoma and non-melanoma skin cancers, three (0.6 %) had lymphomas (0.6 %), and two (0.4 %) had leukemia. Overall 10-year survival after the final course of infliximab was 94 %. Among the 28 deaths (6 %), nine occurred within 12 weeks of an infliximab infusion - two of these deaths were due to infections. Conclusions: Long-term follow-up of patients with Crohn's disease who were treated with infliximab initially between 1998 and 2002 showed persistence of therapy (due to clinical benefit) and an acceptable safety profile, despite the fact that less than one-third initially received three-dose induction followed by scheduled maintenance therapy. Infections and malignancy occurred at rates similar to those previously reported.

Original languageEnglish (US)
Pages (from-to)797-806
Number of pages10
JournalDigestive Diseases and Sciences
Volume58
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Crohn Disease
Infliximab
Neoplasms
Therapeutics
Safety
Mycobacterium avium Complex
Histoplasmosis
Lost to Follow-Up
Skin Neoplasms
Septic Shock
Infection
Medical Records
Melanoma
Lymphoma
Sepsis
Leukemia
Demography

Keywords

  • Adverse events
  • Crohn's disease
  • Infections
  • Infliximab
  • Malignancy
  • Mortality

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

Infliximab for Crohn's disease : The first 500 patients followed up through 2009. / Seminerio, Jennifer L.; Loftus, Jr, Edward Vincent; Colombel, Jean Frédéric; Thapa, Prabin; Sandborn, William J.

In: Digestive Diseases and Sciences, Vol. 58, No. 3, 03.2013, p. 797-806.

Research output: Contribution to journalArticle

Seminerio, Jennifer L. ; Loftus, Jr, Edward Vincent ; Colombel, Jean Frédéric ; Thapa, Prabin ; Sandborn, William J. / Infliximab for Crohn's disease : The first 500 patients followed up through 2009. In: Digestive Diseases and Sciences. 2013 ; Vol. 58, No. 3. pp. 797-806.
@article{e80c5b739b9b4bd78e7d1d41221d8785,
title = "Infliximab for Crohn's disease: The first 500 patients followed up through 2009",
abstract = "Background: The aim of this study was to assess the long-term usage patterns and safety of infliximab in patients with Crohn's disease in clinical practice. Methods: The medical records of 492 unselected patients treated with infliximab at Mayo Clinic were reviewed and abstracted for demographic features, usage patterns, and adverse events. Results: The patients received a median of seven infusions and had a median follow-up of 6.3 years. Twenty-eight patients (6 {\%}) were lost to follow-up, 63 patients (13 {\%}) had no clinical benefit, and 401 patients (80 {\%}) had partial or complete response. Of the responding patients, 114 (28 {\%}) received induction treatment only, 167 (42 {\%}) received initial episodic treatment (62 switched to scheduled maintenance treatment of whom 32 [42 {\%}] were still on infliximab at last follow-up), and 120 (30 {\%}) received scheduled maintenance treatment (56 patients [32 {\%}] still on infliximab at last follow-up). Three patients (0.6 {\%}) developed septic shock and six patients (1.5 {\%}) developed septicemia. One patient (0.2 {\%}) developed Mycobacterium avium complex. Histoplasmosis occurred in three patients (0.6 {\%}). The cumulative 10-year probability for developing cancer after infliximab was 9 {\%}. Among the 31 patients developing malignancies (6 {\%}), 15 (3 {\%}) had solid tumors, 11 (2 {\%}) had melanoma and non-melanoma skin cancers, three (0.6 {\%}) had lymphomas (0.6 {\%}), and two (0.4 {\%}) had leukemia. Overall 10-year survival after the final course of infliximab was 94 {\%}. Among the 28 deaths (6 {\%}), nine occurred within 12 weeks of an infliximab infusion - two of these deaths were due to infections. Conclusions: Long-term follow-up of patients with Crohn's disease who were treated with infliximab initially between 1998 and 2002 showed persistence of therapy (due to clinical benefit) and an acceptable safety profile, despite the fact that less than one-third initially received three-dose induction followed by scheduled maintenance therapy. Infections and malignancy occurred at rates similar to those previously reported.",
keywords = "Adverse events, Crohn's disease, Infections, Infliximab, Malignancy, Mortality",
author = "Seminerio, {Jennifer L.} and {Loftus, Jr}, {Edward Vincent} and Colombel, {Jean Fr{\'e}d{\'e}ric} and Prabin Thapa and Sandborn, {William J.}",
year = "2013",
month = "3",
doi = "10.1007/s10620-012-2405-z",
language = "English (US)",
volume = "58",
pages = "797--806",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Infliximab for Crohn's disease

T2 - The first 500 patients followed up through 2009

AU - Seminerio, Jennifer L.

AU - Loftus, Jr, Edward Vincent

AU - Colombel, Jean Frédéric

AU - Thapa, Prabin

AU - Sandborn, William J.

PY - 2013/3

Y1 - 2013/3

N2 - Background: The aim of this study was to assess the long-term usage patterns and safety of infliximab in patients with Crohn's disease in clinical practice. Methods: The medical records of 492 unselected patients treated with infliximab at Mayo Clinic were reviewed and abstracted for demographic features, usage patterns, and adverse events. Results: The patients received a median of seven infusions and had a median follow-up of 6.3 years. Twenty-eight patients (6 %) were lost to follow-up, 63 patients (13 %) had no clinical benefit, and 401 patients (80 %) had partial or complete response. Of the responding patients, 114 (28 %) received induction treatment only, 167 (42 %) received initial episodic treatment (62 switched to scheduled maintenance treatment of whom 32 [42 %] were still on infliximab at last follow-up), and 120 (30 %) received scheduled maintenance treatment (56 patients [32 %] still on infliximab at last follow-up). Three patients (0.6 %) developed septic shock and six patients (1.5 %) developed septicemia. One patient (0.2 %) developed Mycobacterium avium complex. Histoplasmosis occurred in three patients (0.6 %). The cumulative 10-year probability for developing cancer after infliximab was 9 %. Among the 31 patients developing malignancies (6 %), 15 (3 %) had solid tumors, 11 (2 %) had melanoma and non-melanoma skin cancers, three (0.6 %) had lymphomas (0.6 %), and two (0.4 %) had leukemia. Overall 10-year survival after the final course of infliximab was 94 %. Among the 28 deaths (6 %), nine occurred within 12 weeks of an infliximab infusion - two of these deaths were due to infections. Conclusions: Long-term follow-up of patients with Crohn's disease who were treated with infliximab initially between 1998 and 2002 showed persistence of therapy (due to clinical benefit) and an acceptable safety profile, despite the fact that less than one-third initially received three-dose induction followed by scheduled maintenance therapy. Infections and malignancy occurred at rates similar to those previously reported.

AB - Background: The aim of this study was to assess the long-term usage patterns and safety of infliximab in patients with Crohn's disease in clinical practice. Methods: The medical records of 492 unselected patients treated with infliximab at Mayo Clinic were reviewed and abstracted for demographic features, usage patterns, and adverse events. Results: The patients received a median of seven infusions and had a median follow-up of 6.3 years. Twenty-eight patients (6 %) were lost to follow-up, 63 patients (13 %) had no clinical benefit, and 401 patients (80 %) had partial or complete response. Of the responding patients, 114 (28 %) received induction treatment only, 167 (42 %) received initial episodic treatment (62 switched to scheduled maintenance treatment of whom 32 [42 %] were still on infliximab at last follow-up), and 120 (30 %) received scheduled maintenance treatment (56 patients [32 %] still on infliximab at last follow-up). Three patients (0.6 %) developed septic shock and six patients (1.5 %) developed septicemia. One patient (0.2 %) developed Mycobacterium avium complex. Histoplasmosis occurred in three patients (0.6 %). The cumulative 10-year probability for developing cancer after infliximab was 9 %. Among the 31 patients developing malignancies (6 %), 15 (3 %) had solid tumors, 11 (2 %) had melanoma and non-melanoma skin cancers, three (0.6 %) had lymphomas (0.6 %), and two (0.4 %) had leukemia. Overall 10-year survival after the final course of infliximab was 94 %. Among the 28 deaths (6 %), nine occurred within 12 weeks of an infliximab infusion - two of these deaths were due to infections. Conclusions: Long-term follow-up of patients with Crohn's disease who were treated with infliximab initially between 1998 and 2002 showed persistence of therapy (due to clinical benefit) and an acceptable safety profile, despite the fact that less than one-third initially received three-dose induction followed by scheduled maintenance therapy. Infections and malignancy occurred at rates similar to those previously reported.

KW - Adverse events

KW - Crohn's disease

KW - Infections

KW - Infliximab

KW - Malignancy

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=84876693416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876693416&partnerID=8YFLogxK

U2 - 10.1007/s10620-012-2405-z

DO - 10.1007/s10620-012-2405-z

M3 - Article

C2 - 23053885

AN - SCOPUS:84876693416

VL - 58

SP - 797

EP - 806

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 3

ER -